$298.11 general Payment -- Allergan (AbbVie) to Dr. Stephanie King

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Allergan (AbbVie) made a $298.11 general payment to Stephanie King, a Gastroenterology specialist in Jersey City, NJ. The payment was associated with Tecfidera. The payment of $298.11 to Dr. Stephanie King by Allergan (AbbVie) is for services other than consulting. The payment is associated with Tecfidera, a drug used in Gastroenterology. This payment represents a relatively small financial transaction within the context of pharmaceutical industry payments.

Patient Guidance: What This Payment Means for You

This payment to your doctor is for services rendered and may be related to medications or devices used in your care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

This payment of $298.11 for services other than consulting is a common type of transaction between pharmaceutical companies and Gastroenterologists, often related to product education or support.

Regulatory Context: Sunshine Act Requirements

Payments made by manufacturers to physicians are subject to disclosure under the Open Payments program to ensure transparency in the healthcare industry.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharmaceutical-payments
• physician-compensation
• gastroenterology
• allergan
• abbvie
• tecfidera

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $298.11 payment for?

This was a general payment of $298.11 from Allergan (AbbVie) to Stephanie King, categorized as "Compensation for services other than consulting". It was associated with Tecfidera. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Stephanie King accept pharmaceutical money?

Yes, Stephanie King received this $298.11 payment from Allergan (AbbVie). Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Stephanie King's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $298.11 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Gastroenterology?

To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Stephanie King's relationship with Allergan (AbbVie)?

The payment amount is specific and itemized. This $298.11 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Gastroenterology?

The payment type is 'general', indicating it's not for specific consulting or research.

What should patients do after learning about this payment?

This payment to your doctor is for services rendered and may be related to medications or devices used in your care.

What else should I know about this general payment?

The payment date falls within the current reporting period.

Related Reports

• View Dr. Stephanie King's full payment report
• Allergan (AbbVie) full spending report
• Browse all Gastroenterology payments
• Browse all payments in New Jersey
• Search for other payments